OTC · CWBHF
Charlotte's Web Holdings, Inc.
$0.24-$0.00 (-0.04%)
Charlotte's Web Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.46% below the high.
Loading market information…
TSX · MBX.TO · CAD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 07:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
Microbix Biosystems Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.12% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Microbix Biosystems Inc.’s forward annual dividend is CA$1.10 per share, paid quarterly. The forward yield is 379.31% at the quoted price. Future payments can change.
Dividend payment history is currently unavailable.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Microbix Biosystems Inc.’s next earnings report is currently expected on Dec 17, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Microbix Biosystems Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Microbix Biosystems Inc. is a life science enterprise dedicated to advancing human health globally, including markets across North America and Europe. Established in 1988 and headquartered in Mississauga, Canada, the company specializes in developing and marketing unique biological and technological products. A significant part of its business involves producing essential biological reagents for the diagnostic industry. This encompasses antigens vital for immunoassays, alongside its distinctive Quality Assessment and Proficiency (QAP) products. These QAPs are instrumental for clinical laboratories, providing support for proficiency testing, the development and validation of diagnostic assays, and optimizing routine lab operations. Furthermore, Microbix applies its deep biological knowledge and infrastructure to create additional proprietary offerings. Among these are DxTM, a viral transport medium crucial for stabilizing patient specimens prior to laboratory analysis, and Kinlytic Urokinase, a biopharmaceutical thrombolytic drug employed to treat blood clots. The company channels its QAP sales to accreditation organizations, diagnostic companies, and clinical laboratories via an extensive network of regional distributors.
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Feb 13, 2025 |
| CA$0.01 |
| CA$6.04M+4.21% vs estimate |
| Q4 2024 | Dec 19, 2024 | CA$0.00 | CA$6.29M+12.39% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.24-$0.00 (-0.04%)
Charlotte's Web Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.46% below the high.
CA$0.45-CA$0.02 (-4.26%)
BioMark Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.69% below the high.
CA$0.35-CA$0.02 (-4.11%)
DIAGNOS Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.96% below the high.
CA$4.65-CA$0.21 (-4.32%)
BriaCell Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 74.17% below the high.
CA$0.07CA$0.00 (0.0%)
MediPharm Labs Corp.’s quoted price sits in the lower half of its reported 52-week range, 35.0% below the high.
CA$0.08+CA$0.01 (+6.67%)
Resverlogix Corp.’s quoted price sits in the lower half of its reported 52-week range, 46.67% below the high.
CA$0.35CA$0.00 (0.0%)
Defence Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.37% below the high.
CA$0.38-CA$0.01 (-2.6%)
Rubicon Organics Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.5% below the high.
